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Edited by Barry HalliwellAbstract Here, we examined whether catalase binds SHP2 and
alters SHP2 susceptibility to H2O2. Our results indicated that
serum and ﬁbrinogen commonly evoked catalase binding to
SHP2 in HeLa and A549 cells in a herbimycin-A and TNFa
sensitive manner. Expression of active catalase nearly 15-fold
over control levels in tet-oﬀ HeLa cells substantially increased
the SHP2 binding, and the catalase-associated SHP2 displayed
signiﬁcantly high phosphatase activities with a H2O2-resistance
compared to those with little catalase. Site-directed mutagenesis
at 280 abolished the binding capability of catalase to SHP2–
SH2 in vitro. These results suggest that catalase-280pYIQV
binds SHP2 via integrin-signaling to increase a H2O2-resistant
SHP2 activity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Accumulated evidence indicates that H2O2 acts as a second
messenger of mitogenic signaling [1–3]. In facts, multiple
growth factors commonly elicit a transient generation of in-
tracellular H2O2 [4–7]. Scavengers such as exogenously intro-
duced CAT and N-acetylcysteine substantially decrease P-Tyr
formation and abort MAPK activation and cell proliferation
[4,8,9]. The mechanism by which H2O2 promotes the signaling
still remains unclear, but a parallel formation of P-Tyr with the
generation suggests that H2O2 transiently inhibits PTP [10–13],
whereby RPTK-evoked P-Tyr formation sustains to sequester
SH2- and PTB-domain-containing molecules [4]. Consistent
with this view, all PTP active centers commonly comprise a
single sulfhydryl group [14,15] and its oxidation by H2O2 in-* Corresponding author. Fax: +1-787-848-3919.
E-mail address: yanos@coqui.net (S. Yano).
Abbreviations: CAT, catalase; MAPK, mitogen-activated protein
kinase; P-Tyr, phosphotyrosine; PTP, protein tyrosine phosphatase;
RPTK, receptor protein tyrosine kinase; SH2, Src homology-2; PTB,
phosphotyrosine binding domain; Gab-1, GRB2 associated binder-1;
SHPS-1, SHP substrate-1; EGF-R, epidermal growth factor receptor;
PDGF-R, platelet derived growth factor receptor; HGF-R, hepatocyte
growth factor receptor; FBS, fetal bovine serum; DTT, dithiothreitol;
PDI, protein disulﬁde isomerase; Ras-GAP, Ras-GTPase activating
protein; BTAM, bisphosphoryl tyrosine-based activation motif;
VEGF-R, vascular endothelial growth factor receptor
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PTP activity.
Recent studies, however, demonstrated that a ubiquitous
non-transmembrane PTP, SHP2 (PTPN11), positively regu-
lates the mitogenic signaling [16–18] despite of its antagonistic
action against RPTK-mediated P-Tyr formation. How can
redox-sensitive SHP2 act as a positive regulator during the
mitogenic H2O2 generation? SHP2 comprises one catalytic and
two SH2 domains capable of binding Gab-1 [19], SHPS-1
[20–22], EGF-R [16] and PDGF-R [17]. A free form of SHP2
displays little activity due to folding of its N-terminus to the
cleft of catalytic domain. Binding of ligands unfolds N-ter-
minus from the catalytic domain resulting activity expression,
as deletion of the N-terminus SH2 makes the mutant consti-
tutively express the activity [23]. Importantly, binding to
SHPS-1 enables SHP2 to de-phosphorylate Ras-GAP binding
sites of PDGF-R at Tyr 771 [17] and EGF-R at Tyr 992 [16],
thereby Ras signaling is promoted [16,17]. Since mitogenic
H2O2 generates for 30–45 min [4], during which SHP2 acts on
Ras-GAP binding site, the SHP2 appears tolerant to H2O2.
Otherwise, mitogenic H2O2 quickly inactivates the SHP2. At
present, it is entirely unknown how activated SHP2 can sustain
its activity. If CAT binds SHP2, it could scavenge H2O2 and
protect SHP2 from H2O2-dependent inactivation.
Recently, we have found that human CAT at 447pYVNV
[24] closely resembles to 1374pYVNV of HGF-R [25,26],
1139pYVNQ of Erb2 [27–29] and 1213pYVNA of Flt-PTK
[30,31], which commonly bind SH2-domain of GRB2, an
adaptor protein that connects diverse signaling molecules [32].
Our data indicated that human CAT indeed binds GRB2 in
vitro and co-immunoprecipitates with GRB2 upon integrin-
stimulation in several cell lines [24]. In vitro GRB2 binding of
wild type CAT, but not of Y447F, suggests that 447pYVNV is
the binding site for GRB2-SH2 [24].
In this study, we further tested a hypothesis that CAT binds
SHP2 via integrin-signaling to alter SHP2 sensitivity to H2O2.
The results suggest that, like 988YIGV of PDGF-R, CAT-
280YIQV binds SHP2–SH2 upon integrin-stimulation.2. Materials and methods
2.1. Cells and reagents
A549 and tet-oﬀ HeLa cell line were obtained from ATCC and
Clontech, respectively. pBI, pTK, pUC19M, and the transformer
site-directed mutagenesis kit were from Clontech. Antibodies were
from Calbiochem, Abcam, Santa Cruz Biotech, Qiagen, Promega or
Amersham. Recombinant SHP2–SH2–GST fusion protein andblished by Elsevier B.V. All rights reserved.
328 S. Yano et al. / FEBS Letters 577 (2004) 327–332GSH-agarose were from Santa Cruz Biotech. pCAT10 and
pcDNA4/HisMax were from ATCC and Invitrogen, respectively,
while pQE81L, pQETri System and Ni–NTA–agarose were from
Qiagen. pCMV-SPORT6-SHP2 was from Invitrogen. Biotinylation
kit was from Pierce. Other reagents were from Sigma or Calbio-
chem.
2.2. Cell culture
We used Ham’s F-12 and DMEM supplemented with 10% FBS for
A549 and HeLa cells, respectively. The media contained streptomycin
(100 lg/ml) and penicillin (100 U/ml). In some cases, it contained G418
(400 lg/ml), hygromycin-B (400 lg/ml), and Tet (2 lg/ml).
2.3. Immunoprecipitation
Cells were lysed in a buﬀer consisting of 50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4 10 mM NaF, 0.5%
Triton X-100, 0.5 mM AEBSF, 7.5 lM pepstatin A, 7 lM E-64,18 lM
bestatin, 10.5 lM leupepsin, and 0.4 lM aprotinin. We omitted
Na3VO4 for measurement of SHP2 phosphatase activities. We per-
formed immunoprecipitation as previously reported [24].
2.4. Site-directed mutagenesis
To construct pUC19M/CAT-wild type, pcDNA4/HMCAT (85–
1710) [26] was digested with Kpnl (nt: 1176) and Xbal (nt: 1235), and
the resulting 1657 bp fragment was ligated with pUC19M linearized by
Kpnl (nt: 408) and Xbal (nt: 423). To create Y280F mutant from
pUC19/CAT-wild type, we used the Transformer Site-Directed Mu-
tagenesis Kit together with three primers. The ﬁrst primer corre-
sponded to 50-pC (nt: 873) C ATT GCC ACC GGT AAG TAC CCC
TCC TGG ACT TTT TTC ATC CAG GTC (nt: 919)-30, where the
original sequence of TAC was altered to TTC with creation of Agel
site. The second corresponded to 50-pG (nt: 1642) GCA AAT CTG
AAGCTT CGG GGC CCT GCA CCT G (nt: 1673)-30, where the stop
codon was replaced by a HindIII site. The third corresponded to 50-pG
(nt: 175) AG TGC ACC ATG GGC GGT GTG AAA T (nt: 199)-30.
We performed two rounds of mutagenesis using Escherichia coli
NM522 and DH5a.
2.5. Preparation of recombinant wild type CAT and Y280F
We constructed a bacterial expression vector for an 8His-tagged
CAT at the C-terminus in three steps. First, pUC19M-CAT or
-Y280F was digested with BamHI and EcoRI to produce a fragment
of 188 bp (nts: 85–273). Second, the same clone was digested with
EcoRI and HindIII to produce a fragment of 1379 bp (nts: 273–1652).
Third, the both fragments were ligated to a pQETri System linearized
with BamHI (nt: 1290) and HindIII (nt: 1342). E. coli DH5a trans-
formed with pQE81-CAT, pQETri-CAT or pQETri-CAT/Y280F was
cultured with 1 mM IPTG overnight and lysed in a buﬀer consisting
of lysozyme (1 mg/ml), 50 mM phosphate buﬀer (pH 8.0), NaCl (300
mM) and imidazole (10 mM), followed by sonication. CAT was
puriﬁed using Ni–NTA–agarose as previously described [24].2.6. The eﬀects of TNFa, integrin ligands, CAT levels, and 3-AT on
CAT–SHP2 binding
Establishment of the double stable Tet-oﬀ HeLa cells was reported
earlier [24]. A549 or HeLa cells cultured overnight under FBS-depri-
vation, were incubated for 18–24 h with 10% FBS, laminin (5 lg/ml),
hyaluronic acid (10 lg/ml), elastin (10 lg/ml), GRGDTP (2.93 lM),
GRADSP (2.93 lM) or ﬁbrinogen (4  100 lg/ml). In some cases,
A549 cells were cultured with 10% FBS containing TNFa. The eﬀects
of CAT levels and its activities on CAT–SHP2 binding were deter-
mined as previously reported [24].
2.7. In vitro binding assay
To determine the signiﬁcance of CAT-280Y toward SHP2–SH2
binding, a recombinant SHP2–SH2–GST fusion protein (3 lg) was
incubated for 2 h on ice with wild type CAT (3 lg), Y280F (3 lg), or
human erythrocyte CAT (6 lg) in a lysis buﬀer (500 ll), followed by
overnight incubation with GSH–agarose (10 lg). To evaluate com-
petitive inhibition by wild type CAT, but not by Y280F, toward
SHP2–SH2 binding, SHP2–SH2–GST (3 lg) was ﬁrst incubated with
wild type CAT (6.9 lg ) or Y280F (6.9 lg) together with GSH–agarose
(15 lg) as described above. After rinsing with PBST, the agarose was
then incubated for 4 h on ice with biotinylated wild type CAT (12 lg).2.8. Statistics
To determine the eﬀects of TNFa, CAT levels and its activities on
SHP2-CAT binding, normalized band intensities were expressed as
arbitrary numbers. SHP2 phosphatase activities were compared be-
tween control, DTT and H2O2 groups. The comparison between the
groups was perfomed using ANOVA test followed by the Tukey–
Kramer multiple comparison test. Statistical signiﬁcance was measured
at the level of P ¼ 0:05.3. Results
First, we perfomed co-immunoprecipitation experiments
using A549 cells. We estimated that CAT binding of SHP2
might occur within a similar timeframe as for GRB2, in which
the maximum binding occurred 18–24 h after FBS-stimulation
[24]. To determine the time-course events, A549 cells cultured
under FBS-deprivation overnight were stimulated with 10%
FBS for various periods. The results indicated that, while CAT
little associated with SHP2 under FBS-deprivation (Fig. 1A),
the binding became discernible at 3 h and reached the maxi-
mum level at 24 h. Although the binding level depended on the
FBS concentrations, calf serum was also eﬀective to evoke the
binding (data not shown). To determine whether integerin-li-
gands in FBS were responsible for the binding, we compared
laminin, hyarulonic acid, elastin and ﬁbrinogen with 10% FBS.
The results indicated that laminin and ﬁbrinogen, but not
others, evoked binding (Fig. 1B and C) . In addition, TNFa
negatively regulated the binding in a dose-dependent manner
(Fig. 1D). Thus, CAT binding to SHP2 was a speciﬁc event of
ﬁbrinogen- or laminin-stimulation.
To investigate whether the binding occurs only with A549
cells, we conducted similar experiments using HeLa cells. As
shown in Fig. 2A, HeLa cells cultured in 10% FBS displayed a
discernible binding, whereas those under FBS-deprivation
showed little association. In addition, herbimycin-A, a peptide
containing integrin binding sequence, and its analogue,
somewhat inhibited the binding. Likewise, whereas ﬁbrinogen
evoked binding even under FBS-deprivation, the both peptides
and herbimycin-A again suppressed the binding. These results
suggest that HeLa cells also evoke CAT binding to SHP2.
To determine the eﬀects of CAT levels and its enzyme ac-
tivities on the binding, we used a Tet-oﬀ HeLa cell line capable
of inducing active CAT nearly 15-fold above basal levels upon
Tet-deprivation from culture medium [24]. We determined the
eﬀects by comparing CAT levels co-immunoprecipitated with
SHP2, rather than SHP2 levels co-immunoprecipitated with
CAT, since the latter approach would underestimate the
binding if induced CAT exists as a free form. The results in-
dicated that the cells at a basal CAT level consistently formed
the complex upon FBS stimulation (lane 1 vs. lane 3, Fig. 2B),
and that the cells expressing a high CAT level substantially
increased the binding even without FBS stimulation (lane 1 vs.
lane 5, Fig. 2B). It suggests that the binding critically depends
on CAT levels as observed for GRB2 binding [24]. Upon FBS
stimulation, the binding further increased by nearly 2-fold
compared to the level seen without FBS (lane 5 vs. lane 7,
Fig. 2B). Furthermore, 3-AT signiﬁcantly suppressed the
binding (lane 5 vs. lane 6, and lane 7 vs. lane 8, Fig. 2B). These
results suggest that active CAT levels critically determine the
binding.
To examine the eﬀects of CAT binding on SHP2 activity, we
compared two SHP2 immunoprecipitates, that correspond to
Fig. 2. (A) CAT binds SHP2 upon stimulation of HeLa cells with FBS
or ﬁbrinogen, while herbimycin-A and peptides comprising ﬁbronectin
functional sequence suppress the biding. FBS-deprivation: overnight.
With 10% FBS, ﬁbrinogen (FB), herbimycin-A (Herb.A, 5 lM),
GRGDTP (2.93 lM) or GRADSP (2.93 lM): 24 h. (B) CAT binds
SHP2 depending on CAT levels and activities. Tet-oﬀ HeLa cell with
or without Tet (2 lg/ml): 8 d. FBS-deprivation: 24 h. In the medium
containing 10% FBS, 10 mM 3-AT or both: 18 h. *1; P < 0:001 vs.
lanes 1–6, *2; P < 0:01 vs. lane 8, *3; P < 0:05 vs. lanes 1–4. (C) SHP2
associated with high CAT levels expresses high phosphatase activities
compared to those with low CAT levels. Culture condition: same as in
(B). Incubation: 30 C for 30 min. Phosphatase assay mixture: 30 mM
p-nitrophenyl phosphate, 62mM HEPES, 6.25 mM EDTA, pH 7.0.
DTT; 3 mM DTT, H2O2; 5 lM H2O2. *1; P < 0:01, vs. control, *2;
P < 0:001, vs. H2O2, *3; P < 0:01, vs. tet(+) DTT. (D) SHP2 associ-
ated with high CAT levels show H2O2-resistant activities. *1;
P < 0:001, vs. 2.5 lM H2O2, *2; P < 0:01, vs. tet(+) 0.05 lM H2O2.
Fig. 1. (A) CAT binds SHP2 in A549 cells after FBS-stimulation. FBS-
deprivation: overnight, 10% FBS: the period indicated. (B) CAT binds
SHP2 upon stimulation with FBS or laminin (LA), but not with hy-
aluronic acid (HA) or elastin (EL). FBS-deprivation: overnight, 10%
FBS or an agent indicated: 24 h. (C) CAT binds SHP2 in a ﬁbrinogen-
dose dependent manner. FBS-deprivation: overnight, 10% FBS or ﬁ-
brinogen: 24 h. (D) TNFa negatively regulates CAT binding to SHP2.
FBS-deprivation: overnight, 10% FBS with TNFa: 24 h.
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levels yet diﬀerence in their binding levels as shown in Fig. 2B.
The results indicated that the SHP2 with high levels of CAT
displayed signiﬁcantly high phosphatase activities compared to
those with little CAT in the absence and presence of 3 mM
DTT (Fig. 2C). Despite of these diﬀerences, all samples
showed substantially low but nearly identical phosphatase
activities in the presence of 5 lM H2O2 (Fig. 2C). A dose-re-
sponse analysis indicated that SHP2 became inactivated as
H2O2 concentration increased, and importantly, the SHP2
associated with high levels of CAT exhibited signiﬁcantly high
phosphatase activities compared to those with little CAT in the
presence of 0.05 lM H2O2 (Fig. 2D). Thus, SHP2 is indeed
redox-sensitive as previously reported [10–13] and CAT bind-
ing renders SHP2 resistant to H2O2.Next, we examined whether CAT comprises a sequence
identical to any established SHP2 binding motifs. We found
that CAT 280YIQV resembled to 988YIGV of human PDGF-
R, which binds SHP2–SH2 [17]. To determine the signiﬁcance
330 S. Yano et al. / FEBS Letters 577 (2004) 327–332of CAT 280YIQV for the binding, we compared wild type
CAT with Y280F. Successfully constructed clones of pQE81L
showed IPTG-dependent expression of CAT tagged with
6His at N-termini, and reacted with anti-CAT IgG and Ni–
NTA-HRP (Fig. 3A). In contrast, the clones of pQETri
showed leaky expression of CAT tagged with 8His at C-
termini (Fig. 3A). To purify wild type CAT and Y280F using
Ni–NTA-conjugated agarose, we tested two extraction condi-
tions, one with 8M urea to denature the CAT, and, the other
using lysozyme and sonication to preserve the native form. The
resin retained only CAT tagged at C-termini but not those at
N-termini under native form (Fig. 3B), suggesting that C-ter-
minal 8His tag, but not N-terminal 6His, of native CAT is
accessible to the resin. To determine the diﬀerence between
wild type CAT and Y280F toward SHP2–SH2 binding, we
performed an in vitro binding assay using a recombinant
SHP2–SH2–GST fusion protein. The results indicated that
wild type CAT and human erythrocyte CAT indeed bound
SHP2–SH2–GST directly, while Y280F failed to do so in vitro
(Fig. 3C). To ascertain the diﬀerence, we determined the
competitive inhibition toward SHP2–SH2 binding. The results
indicated that, whereas SHP2–SH2 consistently bound wild
type CAT regardless of whether CAT was biotinylated or not,
pre-incubation of SHP2–SH2 with non-biotinylated wild type
CAT substantially blocked binding of biotinylated wild type
CAT to the SHP2 (Fig. 3D). Importantly, pre-incubation with
Y280F little aﬀected the subsequent binding of biotinylated
wild type CAT (Fig. 3D). These results demonstrate that CAT-
280YIQV is a SHP2–SH2 binding site.Fig. 3. (A) IPTG-dependent expression of wild and mutant CAT
tagged with 6His at N-termini or 8His at C-termini. (B) Ni–NTA–
agarose retains CAT tagged wife 8His, but not those with 6His. (C)
Recombinant full-length wt CAT and human erythrocyte CAT, but
not Y280F, bind SHP2–SH2–GST. (D) A pre-incubation of SHP2–
SH2–GST with wt CAT, but not wife Y280F, inhibits a further
binding of SHP2–SH2–GST to biotinylated wt CAT.4. Discussion
SH2-binding [16,17,19–22] and a redox-status at the active
center [14,15] regulate SHP2 activity. In fact, a mutant lacking
SH2 domain constitutively expresses phosphatase activity, and
binding of SH2 domains activates the enzyme. It suggests that
N-terminus folding into the catalytic domain and its release
control the activity. In addition, all known PTP including
SHP2 commonly comprise a single sulfhydryl group at the
active center [14,15] and become inactive upon its oxidation.
The current data newly suggest CAT-binding based regulation
of SHP2 activity.
The results raise several possibilities and questions. First,
one might wonder why the event is so slow. Unlike other re-
ceptors, integrals play bi-directional regulatory roles known as
outside-in and inside-out signaling through alteration of their
conformation [34–37] via redox-exchanges. Indeed, integrins
b1 and b3, for instance, contain 58 and 56 cysteins out of 798
and 788 amino acids, respectively, with C-x-x-C motif dis-
playing the sulfhydryl-disulﬁde exchange activity [38,39] as
does extracellular PDI [40,41]. In addition, DTT reduction
changes conformation of thrombospondin [42,43], and, per-
haps, of ﬁbronectin, laminin and ﬁbrinogen, too, and increases
cellular access to RGD, a functional sequence to bind integrin
[41]. Thus, integrins binding of their ligands and subsequent
signaling critically rely on sulfhydryl and disulﬁde formation at
appropriate positions. While oxidants and reducing agents
favor for disulﬁde and sulfhydryl formation, respectively,
H2O2 inhibits integrin binding of its ligands [44,45] perhaps
due to random disulﬁde formation hampering redox-ex-
changes at correct positions. Thus, the CAT–SHP2 bindingwould be slow if redox agents were unbalanced or insuﬃcient
for the exchanges within and between integrins and their li-
gands. Facilitation of the binding by active CAT induction and
its suppression by 3-AT (Fig. 2B), support this view.
Second, where does CAT–SHP2 binding ﬁt and play its role
in the integrin-signaling? As shown in Fig. 4, integrins evoke
Fig. 4. Model of CAT interaction with SHP2, GRB2 and SHPS-1, and the eﬀects on mitogenic signaling. Integrin activation evokes phosphorylation
of SHPS-1 and CAT to form signaling aggregates that contain SHP2-CAT complex. Unlike other PTPs, the SHP2 complex resists to mitogenic H2O2
and dephosphorylates RasGAP binding sites of growth factor receptors, leading to Ras-signaling promotion.
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SHP2 [20–22,46]. Upon EGF- or PDGF-stimulation, the
SHP2 dephoshorylates P-Tyr at Ras-GAP binding site within
EGF-R or PDGF-R, resulting in enhancement of Ras- and
Erk-signaling [16,17]. At present, it is unclear how SHP2 re-
cruited to SHPS-1 can work on the Ras-GAP binding sites
upon EGF- or PDGF-stimulation that generates mitogenic
H2O2, despite of its vulnerability to H2O2. One possibility is
that, while BTAM of SHPS-1 or Gab1 binds SHP2 to activate,
these molecules bind also SH3 of GRB2 [57], whose SH2 do-
main binds CAT 447pY [24]. Alternatively, N-SH2 of SHP2
might bind SHPS-1, PDGF-R, Gab1 or IRS-1, and SHP2-C-
SH2 might bind active CAT. While CAT-280pYIQV is dis-
similar to a consensus sequence, L/V-x-pY-x-D-L, of SHPS-1
(428pY and 469pY) [46], Gab1 (627pY) [19] and IRS-1
(1172pY) that bind SHP2-N-SH2, it resembles to 659pYVVV
of Gab1 that binds SHP2-C-SH2. Thus, it is plausible that
integrin-evoked SHPS-1 binding to SHP2 and GRB2 results in
sequestering CAT, a tetramer of 60 kDa subunit [33] that can
bind up to four SHP2 and GRB2, and some of the SHP2 may
work on EGF-R or PDGF-R with a H2O2-resistance. Such a
close proximity between integrins, SHPS-1 and a growth factor
receptor, exists, because, upon ligation of integrin or R-PTKs,
integrin-aVb3 associates with PDGF-R, VEGF-R and insulin
receptor [47–49] while integrin-a5b1 binds EGF-R [50–52].
Conversely, growth-factor stimulation preferentially activates
integrin-associated R-PTKs [48] and R-PTKs activate mem-
brane-proximal integrin-signaling [52]. Thus, CAT may en-
hance SHP2 activity and facilitate focal assemblage of integrin
signaling molecules. A blockade of integrin-evoked CAT–
SHP2 complex formation with TNFa (Fig. 1D), therefore,could be one of TNFa suppressive eﬀects on tumor cell
growth.
Third, it is likely that the binding occurs in tumor cells, but
not in normal cells, despite that tumor cells display low CAT
levels compared to non-tumor cells [53,54]. Whereas diverse
origins of tumor cell lines commonly evoked CAT-GRB2
complex upon integrin-engagement, primary human bronchial
epithelial cells as well as human diploid ﬁbroblast cells dis-
played little binding [24]. In smooth muscle cells, over-
expression of CAT suppresses mitogenic H2O2 and P-Tyr
levels, leading little cell proliferation [4,8]. At present, it is not
clear how the diﬀerence arises despite of common expression of
integrins in all the cells. Interestingly, whereas C-terminal
ANL should destine CAT to peroxisome, CAT induction in
HeLa cells rather increased binding to GRB2 [24] and SHP2
(Fig. 2B). Several scenarios are possible. First, the peroxisome
sequestration could be insuﬃcient or impaired in tumor cells,
displaying less peroxisome than non-tumor cells [55]. Second,
the binding could be associated with undiﬀerentiated or de-
diﬀerentiated cells such as peroxiome-naive cells at early
development or tumor cells, for their growth. Third, integrin-
dependent CAT expression [56] and its traﬃcking factors
might have altered in tumor cells. It is also interesting to know
how an increase of CAT–SHP2 complex upon CAT induction
with oxidative or other insults, aﬀects malignant cells attached
on extracellular matrices such as ﬁbrinogen, ﬁbronectin and
laminin.
In conclusion, the current study demonstrates that CAT
280YIQV binds SHP2–SH2 domain via integrin-signaling. The
binding renders SHP2 resistant to H2O2. This is the ﬁrst report
indicating a direct binding of CAT to SHP2.
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